Safety and Efficacy of Subcutaneously Administered Efalizumab in Adults with Moderate-to-Severe Hand and Foot PsoriasisAn Open-Label Study

被引：0
|
作者：
Rajat Varma
Jennifer A. Cafardi
Wendy Cantrell
Craig Elmets
机构：
[1] University of Alabama Medical Center,UAB Department of Dermatology
来源：
American Journal of Clinical Dermatology | 2008年 / 9卷
关键词：
Psoriasis; Plaque Psoriasis; Dermatology Life Quality Index; Acitretin; Efalizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: Hand and foot psoriasis may be more disabling than psoriasis at other body locations because of its interference with daily functional activities. Most treatment options have limited efficacy, short duration of response, toxicity, intolerability, or inconvenience.
引用
收藏
页码：105 / 109
页数：4
相关论文
共 50 条
  • [31] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [32] Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension
    Hyams, Jeffrey
    Walters, Thomas D.
    Crandall, Wallace
    Kugathasan, Subra
    Griffiths, Anne
    Blank, Marion
    Johanns, Jewel
    Lang, Yinghua
    Markowitz, James
    Cohen, Stanley
    Winter, Harland S.
    Veereman-Wauters, Gigi
    Ferry, George
    Baldassano, Robert
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 651 - 662
  • [33] An Open-Label Study Assessing the Efficacy and Tolerability of a Skincare Regimen in Subjects of Different Ethnicities with Moderate-to-Severe Hyperpigmentation
    Wenner, Kimberly
    Ramberg, Tiffany
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (06) : 2497 - 2507
  • [34] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [35] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
  • [36] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [37] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [38] Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
    Wallace, D. J.
    Hobbs, K.
    Clowse, M. E. B.
    Petri, M.
    Strand, V.
    Pike, M.
    Merrill, J. T.
    Leszczynski, P.
    Neuwelt, C. M.
    Jeka, S.
    Houssiau, F.
    Keiserman, M.
    Ordi-Ros, J.
    Bongardt, S.
    Kilgallen, B.
    Galateanu, C.
    Kalunian, K.
    Furie, R.
    Gordon, C.
    ARTHRITIS CARE & RESEARCH, 2016, 68 (04) : 534 - 543
  • [39] DUPILUMAB PROVIDES LONG-TERM EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Deleuran, Mette
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 34
  • [40] Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
    Blauvelt, A.
    Ladizinski, B.
    Prajapati, V. H.
    Laquer, V.
    Fischer, A.
    Eisman, S.
    Wu, T.
    Vigna, N.
    Teixeira, H. D.
    Liu, J.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
12345